MD Anderson Cancer Center is the First Hospital in USA to Order the
VMS+ Complete Heart Analysis System
Toronto, Ontario, June 6, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that MD Anderson Cancer Center in Houston, Texas has ordered the VMS+ complete heart analysis system for use in clinical evaluations of cancer patients. It is well known that chemotherapy agents are cardiotoxic and lead to a significant number of patients acquiring heart dysfunction.
“We are very pleased to have the number-one ranked cancer center in the United States as the first customer,” commented Desmond Hirson, President of Ventripoint. “With our recent market clearance from the FDA, the doctors at MD Anderson will be using the VMS+ to monitor cardiac function in cancer patients.”
According to the Centers for Disease Control and Prevention, there are 23 million people in the USA diagnosed with cancer and these patients visited their physicians 25 million times in 2015. There are over 1,500 cancer centers in the USA, which monitor these existing patients and treat over 1.7 million new patients annually.
The American Heart Association recently put out a scientific statement acknowledging that some breast cancer therapies can damage the heart and healthcare providers should carefully monitor breast cancer treatment effects on the heart. Breast cancer survivors, especially older women, are more likely to die from cardiovascular diseases such as heart failure rather than breast cancer.
Research studies have shown that changes in chamber volumes and function for the right side of the heart are early indicators of the development of heart problems on the left side of the heart in cancer patients and others. The VMS+ provides rapid and accurate assessments for both sides of the heart using conventional 2D ultrasound. These critical measurements are needed to identify patients who require extra cardiac care before, during and after cancer therapy.
About MD Anderson Cancer Center
MD Anderson has been one of the top two cancer centers in the USA for decades. It receives the highest number of research grants from the National Cancer Institute and is the recognized leader in the diagnosis and treatment of cancer. The hospital sees approximately 1.5 million patients a year and performed 575,000 imaging exams in 2017.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.